Myers – Page 5 – Talk Bio

RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

11 months ago talkbio0Tagged actinium-225, Isotope Supply, Myers, Neoplasms, Neurosecretory Systems, Radiopharmaceuticals, RayzeBio, squibb

RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors

ASCO 2024: Bristol Myers Squibb’s Opdivo-Yervoy Combo Challenges Roche and AstraZeneca in First-Line Liver Cancer Treatment

11 months ago talkbio0Tagged 2024, ASCO, AstraZeneca, CheckMate-9DW, first-line, Immunotherapy, Liver and Intrahepatic Biliary Tract Carcinoma, Myers, Opdivo-Yervoy, Roche (company), squibb

ASCO 2024, Opdivo-Yervoy, Bristol Myers Squibb, Liver Cancer, First-Line Treatment, Roche, AstraZeneca, Immunotherapy, CheckMate-9DW

BMS Details Confirmatory Trial Win for KRAS Inhibitor Krazati

11 months ago talkbio0Tagged Accelerated, Approved, Confirmatory Trial, Inhibitor, K-ras Oncogene, KRAZATI, Myers, Non-Small Cell Lung Carcinoma, Pharmacotherapy, Progression-Free Survival, squibb, United States Food and Drug Administration

Bristol Myers Squibb, Krazati, KRAS inhibitor, confirmatory trial, non-small cell lung cancer (NSCLC), progression-free survival (PFS), chemotherapy, accelerated approval, FDA

Bristol Myers’ Breyanzi Expands Indications to Include Follicular Lymphoma

12 months ago talkbio0Tagged Approved, Breyanzi, Cancer Therapeutic Procedure, CAR-T, Immunotherapy, Lymphoma, Follicular, Myers, United States Food and Drug Administration

Bristol Myers, Breyanzi, CAR-T therapy, follicular lymphoma, FDA approval, cancer treatment, immunotherapy.

Bristol Myers’ Breyanzi Approved by FDA for Follicular Lymphoma, Joining Gilead and Novartis in CAR-T Treatment

12 months ago talkbio0Tagged Breyanzi, Cancer Therapeutic Procedure, CAR-T, Gilead, Immunotherapy, Lymphoma, Follicular, Myers, Novartis, United States Food and Drug Administration

Bristol Myers, Breyanzi, FDA, follicular lymphoma, CAR-T, Gilead, Novartis, cancer treatment, immunotherapy

Editas Medicine and Bristol Myers Squibb Expand T Cell Therapy Collaboration; KalVista Pharmaceuticals Seeks Partnership for Preclinical Hereditary Angioedema Program

12 months ago talkbio0Tagged Angioedemas, Hereditary, Collaboration, Editas Medicine, KalVista, Myers, Partnership, preclinical program, squibb, T cell therapy

Editas Medicine, Bristol Myers Squibb, T cell therapy, collaboration, KalVista Pharmaceuticals, preclinical program, hereditary angioedema (HAE), partnership.